These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 35449015)

  • 1. Aspirin to target arterial events in chronic kidney disease (ATTACK): study protocol for a multicentre, prospective, randomised, open-label, blinded endpoint, parallel group trial of low-dose aspirin vs. standard care for the primary prevention of cardiovascular disease in people with chronic kidney disease.
    Gallagher H; Dumbleton J; Maishman T; Whitehead A; Moore MV; Fuat A; Fitzmaurice D; Henderson RA; Lord J; Griffith KE; Stevens P; Taal MW; Stevenson D; Fraser SD; Lown M; Hawkey CJ; Roderick PJ
    Trials; 2022 Apr; 23(1):331. PubMed ID: 35449015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aspirin for Primary Prevention of Cardiovascular Disease and Renal Disease Progression in Chronic Kidney Disease Patients: a Multicenter Randomized Clinical Trial (AASER Study).
    Goicoechea M; de Vinuesa SG; Quiroga B; Verde E; Bernis C; Morales E; Fernández-Juárez G; de Sequera P; Verdalles U; Delgado R; Torres A; Arroyo D; Abad S; Ortiz A; Luño J
    Cardiovasc Drugs Ther; 2018 Jun; 32(3):255-263. PubMed ID: 29943364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
    Ikeda Y; Shimada K; Teramoto T; Uchiyama S; Yamazaki T; Oikawa S; Sugawara M; Ando K; Murata M; Yokoyama K; Ishizuka N
    JAMA; 2014 Dec; 312(23):2510-20. PubMed ID: 25401325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomised controlled trial comparing efficacy and safety of high versus low Low-Molecular Weight Heparin dosages in hospitalized patients with severe COVID-19 pneumonia and coagulopathy not requiring invasive mechanical ventilation (COVID-19 HD): a structured summary of a study protocol.
    Marietta M; Vandelli P; Mighali P; Vicini R; Coluccio V; D'Amico R;
    Trials; 2020 Jun; 21(1):574. PubMed ID: 32586394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Elderly Japanese Patients with Atherosclerotic Risk Factors: Subanalysis of a Randomized Clinical Trial (JPPP-70).
    Sugawara M; Goto Y; Yamazaki T; Teramoto T; Oikawa S; Shimada K; Uchiyama S; Ando K; Ishizuka N; Murata M; Yokoyama K; Uemura Y; Ikeda Y;
    Am J Cardiovasc Drugs; 2019 Jun; 19(3):299-311. PubMed ID: 30565155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aspirin for prophylactic use in the primary prevention of cardiovascular disease and cancer: a systematic review and overview of reviews.
    Sutcliffe P; Connock M; Gurung T; Freeman K; Johnson S; Kandala NB; Grove A; Gurung B; Morrow S; Clarke A
    Health Technol Assess; 2013 Sep; 17(43):1-253. PubMed ID: 24074752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aspirin for the primary prevention of cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis.
    Pallikadavath S; Ashton L; Brunskill NJ; Burton JO; Gray LJ; Major RW
    Eur J Prev Cardiol; 2022 Feb; 28(17):1953-1960. PubMed ID: 34448849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
    ; Bowman L; Mafham M; Wallendszus K; Stevens W; Buck G; Barton J; Murphy K; Aung T; Haynes R; Cox J; Murawska A; Young A; Lay M; Chen F; Sammons E; Waters E; Adler A; Bodansky J; Farmer A; McPherson R; Neil A; Simpson D; Peto R; Baigent C; Collins R; Parish S; Armitage J
    N Engl J Med; 2018 Oct; 379(16):1529-1539. PubMed ID: 30146931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis.
    Greenhalgh J; Bagust A; Boland A; Martin Saborido C; Oyee J; Blundell M; Dundar Y; Dickson R; Proudlove C; Fisher M
    Health Technol Assess; 2011 Sep; 15(31):1-178. PubMed ID: 21888837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on aspirin in the treatment and prevention of cardiovascular disease.
    Hennekens CH
    Am J Manag Care; 2002 Dec; 8(22 Suppl):S691-700. PubMed ID: 12512736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ticagrelor monotherapy in patients with concomitant diabetes mellitus and chronic kidney disease: a post hoc analysis of the GLOBAL LEADERS trial.
    Gao C; Tomaniak M; Takahashi K; Kawashima H; Wang R; Hara H; Ono M; Montalescot G; Garg S; Haude M; Slagboom T; Vranckx P; Valgimigli M; Windecker S; van Geuns RJ; Hamm C; Steg PG; Onuma Y; Angiolillo DJ; Serruys PW
    Cardiovasc Diabetol; 2020 Oct; 19(1):179. PubMed ID: 33066794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aspirin for the Primary Prevention of Cardiovascular Diseases in Patients with Chronic Kidney Disease: An Updated Meta-analysis.
    Bellos I; Marinaki S; Lagiou P; Benetou V
    Am J Cardiovasc Drugs; 2024 Mar; 24(2):241-253. PubMed ID: 38296933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Male and Female Patients: A Secondary Analysis of the ADAPTABLE Randomized Clinical Trial.
    Benziger CP; Stebbins A; Wruck LM; Effron MB; Marquis-Gravel G; Farrehi PM; Girotra S; Gupta K; Kripalani S; Munoz D; Polonsky TS; Sharlow A; Whittle J; Harrington RA; Rothman RL; Hernandez AF; Jones WS
    JAMA Cardiol; 2024 Sep; 9(9):808-816. PubMed ID: 38985488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.
    Palmer SC; Navaneethan SD; Craig JC; Johnson DW; Perkovic V; Hegbrant J; Strippoli GF
    Cochrane Database Syst Rev; 2014 May; (5):CD007784. PubMed ID: 24880031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale, design, and baseline data of the Japanese Primary Prevention Project (JPPP)-a randomized, open-label, controlled trial of aspirin versus no aspirin in patients with multiple risk factors for vascular events.
    Teramoto T; Shimada K; Uchiyama S; Sugawara M; Goto Y; Yamada N; Oikawa S; Ando K; Ishizuka N; Yamazaki T; Yokoyama K; Murata M; Ikeda Y
    Am Heart J; 2010 Mar; 159(3):361-369.e4. PubMed ID: 20211296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials.
    Sanmuganathan PS; Ghahramani P; Jackson PR; Wallis EJ; Ramsay LE
    Heart; 2001 Mar; 85(3):265-71. PubMed ID: 11179262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aspirin and cardiovascular primary prevention in non-endstage chronic kidney disease: A meta-analysis.
    Major RW; Oozeerally I; Dawson S; Riddleston H; Gray LJ; Brunskill NJ
    Atherosclerosis; 2016 Aug; 251():177-182. PubMed ID: 27341534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
    ; Baigent C; Blackwell L; Collins R; Emberson J; Godwin J; Peto R; Buring J; Hennekens C; Kearney P; Meade T; Patrono C; Roncaglioni MC; Zanchetti A
    Lancet; 2009 May; 373(9678):1849-60. PubMed ID: 19482214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
    Antithrombotic Trialists' Collaboration
    BMJ; 2002 Jan; 324(7329):71-86. PubMed ID: 11786451
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.